The Venture Codex Logo

The Venture Codex

Intermediate Capital Group

Procession House, 55 Ludgate Hill, London, England, EC4M 7JW, United Kingdom

Overview

Independent mezzanine finance and leveraged credit provider.

Founded

1989

Deals · 12mo

1

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series B

Geographic focus

Canada
France
India
Ireland
...

Sector focus

Finance
Financial Services
Impact Investing

Investment portfolio

13rounds
NAMEDATESIZE
Mediar Therapeutics
Jan 2026Led
$76 MSeries B
Draig Therapeutics
Jun 2025Participated
$140 MSeries A
F2G
Sep 2024Participated
$100 MOther Equity
Greywolf Therapeutics
May 2024Led
$50 MSeries B
Visma
Dec 2023Participated
$1.1 BOther Equity
Amp Solar Group
Jun 2023Participated
$250 MOther Equity
AmpIn Energy Transition (Formerly Amp Energy India)
Jun 2023Participated
$250 MOther Equity
Amolyt Pharma
Jan 2023Led
$137 MSeries C
Eliem Therapeutics
May 2021Led
$60 MSeries B
Eliem Therapeutics
Apr 2021Participated
$80 MOther Equity
Workhuman
Jul 2020Led
$120 MOther Equity
Vitaldent
Dec 2013Led
$136 MOther Equity
Mediar Therapeutics
Jan 2026Led
$76 MSeries B
Draig Therapeutics
Jun 2025Participated
$140 MSeries A
F2G
Sep 2024Participated
$100 MOther Equity
Greywolf Therapeutics
May 2024Led
$50 MSeries B
Visma
Dec 2023Participated
$1.1 BOther Equity
Amp Solar Group
Jun 2023Participated
$250 MOther Equity
AmpIn Energy Transition (Formerly Amp Energy India)
Jun 2023Participated
$250 MOther Equity
Amolyt Pharma
Jan 2023Led
$137 MSeries C
Eliem Therapeutics
May 2021Led
$60 MSeries B
Eliem Therapeutics
Apr 2021Participated
$80 MOther Equity
Workhuman
Jul 2020Led
$120 MOther Equity
Vitaldent
Dec 2013Led
$136 MOther Equity
13
Items
...
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Intermediate Capital Group: 13 funding rounds are recorded in the selected participation categories.All available history.
Intermediate Capital Group: 13 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01
Series B30
Series C+11
Other Equity25

Monthly Deal Activity

Intermediate Capital Group: 13 deals are recorded across 169 months.All available history.
Intermediate Capital Group: 13 deals are recorded across 169 months. All available history
MonthDeals
Oct '121
Nov '120
Dec '120
Jan '130
Feb '130
Mar '130
Apr '130
May '130
Jun '130
Jul '130
Aug '130
Sep '130
Oct '130
Nov '130
Dec '131
Jan '140
Feb '140
Mar '140
Apr '140
May '140
Jun '140
Jul '140
Aug '140
Sep '140
Oct '140
Nov '140
Dec '140
Jan '150
Feb '150
Mar '150
Apr '150
May '150
Jun '150
Jul '150
Aug '150
Sep '150
Oct '150
Nov '150
Dec '150
Jan '160
Feb '160
Mar '160
Apr '160
May '160
Jun '160
Jul '160
Aug '160
Sep '160
Oct '160
Nov '160
Dec '160
Jan '170
Feb '170
Mar '170
Apr '170
May '170
Jun '170
Jul '170
Aug '170
Sep '170
Oct '170
Nov '170
Dec '170
Jan '180
Feb '180
Mar '180
Apr '180
May '180
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '190
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '201
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '211
May '211
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '231
Feb '230
Mar '230
Apr '230
May '230
Jun '232
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '231
Jan '240
Feb '240
Mar '240
Apr '240
May '241
Jun '240
Jul '240
Aug '240
Sep '241
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '251
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '261
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Intermediate Capital Group: Health & Life Sciences is the largest displayed sector by deal count (8 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Intermediate Capital Group: Health & Life Sciences is the largest displayed sector by deal count (8 deals). All available history
SectorDeals
Health & Life Sciences8
Enterprise Software3
Clean Energy & Sustainability2
Professional Services2
Education & Workforce1
Hardware & Robotics1
Data, Analytics & IT1

Deal Size Distribution

Intermediate Capital Group: 13 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Intermediate Capital Group: 13 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M1
$25M-$50M0
$50M-$100M4
$100M-$250M6
$250M-$500M1
$500M-$1B0
$1B+1

Deals By Geography

Intermediate Capital Group: Europe has the largest recorded deal count among the displayed regions (7 deals).All available history.

Top 4 of 4 regions; European countries are grouped as Europe.

Intermediate Capital Group: Europe has the largest recorded deal count among the displayed regions (7 deals). All available history
RegionDeals
Europe7
United States4
Canada1
India1
Intermediate Capital Group: 20 co-investors are shown, with Access Biotechnology sharing 3 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Intermediate Capital Group: 20 co-investors are shown, with Access Biotechnology sharing 3 recorded deals. All available history
Co-investorShared deals
Access Biotechnology3
Andera Partners2
Asian Infrastructure Investment Bank2
Canaan Partners2
Novo Holdings2
RA Capital Management2
Sofinnova Partners2
Sumitomo Mitsui Banking Corporation2
Acorn Bioventures1
Advent Life Sciences1
Alexandria Venture Investments1
Altaroc1
Amplitude Ventures1
AMR Action Fund1
Asahi Kasei Pharma1
ATEM Capital1
Bpifrance1
Brace Pharma Capital1
British Patient Capital1
Credit Agricole Creation1

Investment Strategy

Intermediate Capital Group: Led accounts for 46% and participating for 54% of round participation.All available history.
Intermediate Capital Group: Led accounts for 46% and participating for 54% of round participation. All available history
CategoryDeals (count)Share (%)
Led646%
Participating754%
Intermediate Capital Group: Single-lead accounts for 50% and co-led for 50% of lead dynamics.All available history.
Intermediate Capital Group: Single-lead accounts for 50% and co-led for 50% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead350%
Co-led350%

Team

Alan Jones

Senior Managing Director

Allan Marchington
David Bicarregui

Chief Financial Officer

Eimear Palmer

Managing Director, Head of Responsible Investing

Joseph Pallotta

Principal

Justin Dowley

Chairman

Liam McGivern

European Mid-Market Private Equity Investor

Toby Sykes

Managing Director, Life Sciences

Vivien Blossier

Head of European LP Secondary Investments